	US 11,672,885 B2
	Therapeutic putties containing additives including processed human blood plasma
Richard Kronenthal, Fair Lawn, NJ (US); John Pacifico, Greenwich, CT (US); and Aniq Darr, Riverdale, NY (US)
Assigned to Abyrx, Inc., Stamford, CT (US)
Filed by Abyrx, Inc., Stamford, CT (US)
Filed on May 30, 2018, as Appl. No. 15/992,996.
Claims priority of provisional application 62/512,482, filed on May 30, 2017.
Prior Publication US 2018/0344898 A1, Dec. 6, 2018
Int. Cl. A61L 27/36 (2006.01); A61L 24/00 (2006.01); A61L 27/02 (2006.01); A61L 27/10 (2006.01); A61L 27/12 (2006.01); A61L 27/18 (2006.01); A61L 27/50 (2006.01); A61L 27/54 (2006.01); A61L 27/58 (2006.01); C08L 33/12 (2006.01); C08L 33/14 (2006.01); C08L 71/02 (2006.01); C08L 75/04 (2006.01)

CPC A61L 27/3691 (2013.01) [A61L 24/0005 (2013.01); A61L 27/025 (2013.01); A61L 27/10 (2013.01); A61L 27/12 (2013.01); A61L 27/18 (2013.01); A61L 27/3616 (2013.01); A61L 27/3687 (2013.01); A61L 27/505 (2013.01); A61L 27/54 (2013.01); A61L 27/58 (2013.01); C08L 33/12 (2013.01); C08L 33/14 (2013.01); C08L 71/02 (2013.01); C08L 75/04 (2013.01); A61L 2400/04 (2013.01); C08L 2203/02 (2013.01)]

22 Claims

1. A plurality of biocompatible, settable component parts, comprising a first component and a second component,

wherein the first component comprises 30% to 40% of a polyfunctional isocyanate compound, 0.5% to 3% of one or more polyols, 50-65% of a particulate component, based upon the total weight of the first component,

wherein the second component comprises 3% to 5% of a polyfunctional isocyanate compound, 0.5 to 15% of one or more polyols, 70% to 85% of a particulate component, based upon the total weight of the second component,

wherein the particulate component comprises one or more particulate matters, and

wherein the first and the second components are mixed together prior to use to form a bioabsorbable, homogenous, hemostatic and adhesive composition.